Myeloid checkpoint inhibitors and immuno-oncology antibodies
Strategic Profile
The company has a focused pipeline targeting Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB) myeloid checkpoints, with lead programs IO-108 and IO-202 advancing through clinical trials. Immune-Onc has secured strategic partnerships with leading biopharmaceutical companies including BeiGene and Regeneron, and maintains research collaborations with top-tier institutions including Memorial Sloan Kettering Cancer Center.
Cyborg Score Rationale
Immune-Onc demonstrates solid fundamentals with $138M raised from established investors and a differentiated pipeline addressing an underexploited myeloid checkpoint target space. However, as a 13-person Series B company, it faces typical development-stage risks including regulatory uncertainty, lengthy clinical timelines, and capital intensity typical of immuno-oncology ventures.
Top Insights
Lead candidate IO-108 began a global Phase 1b/2 trial (January 2026) in solid tumors, advancing from completed Phase 1 monotherapy data
Focused pipeline targeting underexploited LILRB myeloid checkpoints, a validated but less crowded segment than PD-1/PD-L1 checkpoint space
Strategic manufacturing and development partnerships with Regeneron and BeiGene de-risk global development and commercialization
Lean 13-person team reflects early-stage status; capital efficiency and partnership strategy appear central to near-term growth
Named Competitors
Arcus Biosciences — Immuno-oncology company developing checkpoint inhibitors and antibodies
Jounce Therapeutics — Immuno-oncology company targeting checkpoint molecules and myeloid modulation